– Q4 2020 Total Revenue of $74.0 million
–
– Q4 2020 Rental Revenue of $9.4 million, up
71.7% from the same period in 2019 –
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today reported financial results for the three- and
twelve-month periods ended December 31, 2020.
Fourth Quarter 2020 Highlights
- Total revenue of $74.0 million, down 6.3% from the same period
in 2019, primarily due to the impacts of the COVID-19 pandemic
- Domestic business-to-business sales of $24.2 million, up 17.9%
from the same period 2019
- Rental revenue of $9.4 million, up 71.7% from the same period
in 2019
- Net loss of $5.1 million and Adjusted EBITDA of $3.0 million
(see accompanying table for reconciliation of GAAP and non-GAAP
measures)
- Cash, cash equivalents, and marketable securities were $231.2
million with no debt outstanding as of December 31, 2020
Full Year 2020 Highlights
- Total revenue of $308.5 million, down 14.8% versus 2019,
primarily due to the impacts of the COVID-19 pandemic
- Increased focus on rentals leading to a 32.3% increase in
rental revenue, primarily due to a 27.3% increase in patients on
service and an improved rental gross margin of 52.1% in 2020
compared to 34.1% in 2019
- $22.1 million increase in cash, cash equivalents, and
marketable securities as of December 31, 2020 compared to December
31, 2019
“While the COVID-19 pandemic continued to have a significant
effect on our business in the fourth quarter of 2020, primarily in
the direct-to-consumer and international business-to-business sales
channels, we are pleased with the rebound in performance that we
saw in our domestic business-to-business channel which exhibited
double-digit growth in the fourth quarter of 2020 over the
comparable period of the prior year,” said Inogen’s newly appointed
President and Chief Executive Officer, Nabil Shabshab.
“Additionally, our recent focus on the rental channel produced
strong operating performance with rental revenue growing
significantly in the fourth quarter of 2020 versus the comparable
period in the prior year.”
Fourth Quarter 2020 Financial Results
Total revenue for the three months ended December 31, 2020
declined 6.3% to $74.0 million from $78.9 million in the same
period in 2019.
Domestic business-to-business sales in the fourth quarter of
2020 increased 17.9% to $24.2 million compared to $20.6 million in
the fourth quarter of 2019. The Company believes this increase was
primarily a result of the unfulfilled orders in the fourth quarter
of 2019, which led to an easier comparable period in the fourth
quarter of 2020, and increased demand for portable oxygen
concentrators (“POCs”) as hospital systems and stationary oxygen
concentrator supply were strained to keep up with the rapid
increase in COVID-19 cases. In addition, the Company believes the
resolution of the competitive bidding uncertainty in October 2020
also contributed to increased demand in the quarter, which was
partially offset by lower reseller customer demand in the
comparative period.
International business-to-business sales in the fourth quarter
of 2020 decreased by 20.4% (23.8% decrease on a constant currency
basis) to $13.6 million compared to $17.1 million in the fourth
quarter of 2019. The Company believes the decrease was primarily
driven by the resurgence of the COVID-19 pandemic in the quarter
causing additional lockdowns in many European countries along with
reduced operational capacity of certain European respiratory
assessment centers.
Direct-to-consumer sales decreased 25.2% to $26.8 million in the
fourth quarter of 2020 from $35.8 million in the fourth quarter of
2019. The Company believes the decrease was primarily driven by the
impact of the COVID-19 public health emergency (“PHE”) on consumer
travel, mobility, and consumer confidence, as well as an
approximately 6% reduction in average inside sales representative
headcount versus the fourth quarter of 2019, and an increased focus
of inside sales representatives’ time on new rental setups. As of
December 31, 2020, the Company had a total of 300 inside sales
representatives, down from 329 as of December 31, 2019.
Rental revenue in the fourth quarter of 2020 increased to $9.4
million from $5.4 million in the same period in 2019, an increase
of 71.7%, primarily due to increased patients on service, higher
billable patients as a percent of total patients on service, higher
Medicare reimbursement rates, and lower rental revenue adjustments.
As of December 31, 2020, the Company had approximately 32,200
patients on service, which was up 9.2% sequentially compared to
September 30, 2020, and up 27.3% compared to December 31, 2019. The
increase in patients on service was primarily driven by greater
utilization of leads for rental opportunities and initiatives to
increase physician awareness by the Company’s sales force. As of
December 31, 2020, the Company had a total of 24 physician sales
representatives, up from 17 as of December 31, 2019.
Total gross margin was 46.0% in the fourth quarter of 2020
versus 43.0% in the comparative period in 2019. Sales revenue gross
margin increased to 44.5% in the fourth quarter of 2020 versus
43.0% in the fourth quarter of 2019. This increase was primarily
due to lower manufacturing cost per unit in the quarter due to
certain manufacturing inefficiencies experienced in the comparable
period of 2019 and lower warranty cost per unit. These increases
were partially offset by higher labor and overhead cost per unit
and lower average selling prices due to an increased mix of
domestic business-to-business sales, which have a lower gross
margin than direct-to-consumer sales. Rental revenue gross margin
increased to 56.5% in the fourth quarter of 2020 versus 43.3% in
the fourth quarter of 2019, primarily due to higher billable
patients as a percent of total patients on service, higher Medicare
reimbursement rates, lower rental revenue adjustments, and lower
depreciation expense per patient on service.
Total operating expense increased to $39.6 million in the fourth
quarter of 2020 versus $39.2 million in the fourth quarter of 2019,
primarily due to an increase in the fair value of the New Aera
earnout liability and higher personnel-related expenses, partially
offset by lower legal and consulting expenses and a reduction in
product incentives and advertising. Research and development
expense increased to $3.7 million in the fourth quarter of 2020
versus $3.6 million in the comparative period in 2019, primarily
associated with increased product development costs. Sales and
marketing expense decreased to $25.4 million in the fourth quarter
of 2020 versus $25.5 million in the comparative period in 2019,
primarily due to decreased product incentives and advertising
expenditures, partially offset by increased personnel-related
expenses. Advertising expenditures were $9.3 million in the fourth
quarter of 2020 compared to $9.5 million in the fourth quarter of
2019. General and administrative expense increased to $10.5 million
in the fourth quarter of 2020 versus $10.1 million in the
comparative period in 2019, primarily due to a $0.4 million
increase in the fair value of the New Aera earnout liability and
increased recruiting costs, partially offset by lower legal and
consulting expenses.
The Company reported an operating loss for the three months
ended December 31, 2020 of $5.5 million and Adjusted EBITDA of $3.0
million.
In the fourth quarter of 2020, the Company reported a net loss
of $5.1 million with loss per diluted common share of $0.23.
As of December 31, 2020, the Company had cash, cash equivalents,
and marketable securities were $231.2 million with no debt
outstanding.
Financial Outlook for 2021
Because of the unprecedented market uncertainties, the Company
is unable to provide guidance for the full year 2021. Given the
uncertain scope and duration of the COVID-19 pandemic, the Company
is unable to estimate the impact on its financial results,
including revenue, net income or loss, and Adjusted EBITDA
estimates for such period.
As the Company saw in the fourth quarter of 2020, demand has
increased so far in the first quarter of 2021 from the Company’s
domestic HME partners in part, due to increased demand for POCs as
hospital systems and stationary oxygen concentrator supply have
been strained to keep up with the rapid increase in COVID-19 cases.
While the Company does not know how long this increased need for
POCs will continue, the Company expects its domestic
business-to-business sales to increase in the first quarter of 2021
versus the comparative period in the prior year. In addition, the
Company expects its rental revenue to grow in the first quarter of
2021 compared to the same period in the prior year due to increased
patients on service, higher billable patients as a percent of total
patients on service, and higher average reimbursement rates.
However, the Company also expects its international
business-to-business and direct-to-consumer sales channels in the
first quarter of 2021 to decrease compared to the same period in
the prior year as a result of the continued COVID-19 impact on
these channels.
While the Company expects the COVID-19 pandemic and any
potential for further, prolonged lockdowns would have a negative
impact on its sales revenue, the Company believes it is prudent to
make investments to support its strategy to focus on rentals at the
onset-of-care. As part of this strategic initiative, the Company
plans to invest to expand its physician sales force and to build
the infrastructure to enable it to offer physicians the necessary
solutions to better serve their patients’ needs. Furthermore, the
Company plans to continue to make investments to broaden its
portfolio with innovative products and to support its products with
expanded clinical evidence. Given such investment initiatives, the
Company expects increased operating expense for the year in 2021.
In addition, the Company incurred minimal expenses related to bonus
and performance-based stock compensation in 2020, and it expects
such costs to increase in 2021 along with certain expenses related
to the recent CEO transition.
Conference Call
Individuals interested in listening to the conference call today
at 1:30pm PT/4:30pm ET may do so by dialing (877) 841-3961 for
domestic callers or (201) 689-8589 for international callers. To
listen to a live webcast, please visit the Investor Relations
section of Inogen's website at: http://investor.inogen.com/.
A replay of the call will be available beginning February 24,
2021 at 3:30pm PT/6:30pm ET through March 10, 2021. To access the
replay, dial (877) 660-6853 or (201) 612-7415 and reference Access
Code: 13714750. The webcast will also be available on Inogen's
website for one year following the completion of the call.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
About Inogen
We are a medical technology company offering innovative
respiratory products for use in the homecare setting. We primarily
develop, manufacture and market innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the Company’s
expectations related to revenue and operating expenses in 2021, the
anticipated impact of the COVID-19 pandemic on the Company’s
business, including the impact on supply and demand for the
Company’s products in its various business channels, the Company’s
operating and sales strategy in respect to the COVID-19 pandemic,
expectations regarding international sales and tender activity,
expectations regarding changes to reimbursement rates, expectations
related to the Company’s physician sales force, expectations for
the first quarter of 2021 in the Company’s revenue channels,
expectations regarding the Company’s stock-based compensation
expenses and other compensation expenses, and expectations related
to the Company’s rental strategy and growth prospects. Any
statements contained in this communication that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “intends,” “potential,” “possible,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to,
risks arising from the possibility that Inogen will not realize
anticipated revenue; the risks related to the COVID-19 pandemic;
the impact of changes in reimbursement rates and reimbursement and
regulatory policies; the possible loss of key employees, customers,
or suppliers; risks relating to Inogen’s acquisition of New Aera,
Inc. and the integration of New Aera’s business and operations
within those of Inogen; risks relating to reimbursement coding of
the Tidal Assist© Ventilator (TAV); the possibility that Inogen
will not realize anticipated revenue from the technology acquired
from New Aera or that expenses and costs will exceed Inogen’s
expectations; intellectual property risks if Inogen is unable to
secure and maintain patent or other intellectual property
protection for the intellectual property used in its products; and
intellectual property risks relating to the acquisition of New
Aera, including the risk of intellectual property litigation. In
addition, Inogen's business is subject to numerous additional risks
and uncertainties, including, among others, risks relating to
market acceptance of its products; competition; its sales,
marketing and distribution capabilities; its planned sales,
marketing, and research and development activities; interruptions
or delays in the supply of components or materials for, or
manufacturing of, its products; seasonal variations; unanticipated
increases in costs or expenses; and risks associated with
international operations. Information on these and additional
risks, uncertainties, and other information affecting Inogen’s
business operating results are contained in its Quarterly Report on
Form 10-Q for the period ended September 30, 2020, and in its other
filings with the Securities and Exchange Commission. Additional
information will also be set forth in Inogen’s Annual Report on
Form 10-K for the year ended December 31, 2020, to be filed with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Inogen disclaims any
obligation to update these forward-looking statements except as may
be required by law.
Use of Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance
with U.S. GAAP and also on a non-GAAP basis for the three and
twelve months ended December 31, 2020 and 2019. Management believes
that non-GAAP financial measures, taken in conjunction with U.S.
GAAP financial measures, provide useful information for both
management and investors by excluding certain non-cash and other
expenses that are not indicative of Inogen's core operating
results. Management uses non-GAAP measures to compare Inogen's
performance relative to forecasts and strategic plans, to benchmark
Inogen's performance externally against competitors, and for
certain compensation decisions. Non-GAAP information is not
prepared under a comprehensive set of accounting rules and should
only be used to supplement an understanding of Inogen's operating
results as reported under U.S. GAAP. Inogen encourages investors to
carefully consider its results under U.S. GAAP, as well as its
supplemental non-GAAP information and the reconciliation between
these presentations, to more fully understand its business.
Reconciliations between U.S. GAAP and non-GAAP results are
presented in the accompanying tables of this release. For future
periods, Inogen is unable to provide a reconciliation of non-GAAP
measures without unreasonable effort as a result of the uncertainty
regarding, and the potential variability of, the amounts of
interest income, interest expense, depreciation and amortization,
stock-based compensation, provision for income taxes, and certain
other infrequently occurring items, such as acquisition-related
costs, that may be incurred in the future.
– Financial Tables Follow –
Consolidated Balance
Sheets
(amounts in thousands)
December 31,
December 31,
2020
2019
Assets
Current assets
Cash and cash equivalents
$
211,962
$
198,037
Marketable securities
19,257
11,057
Accounts receivable, net
29,717
34,325
Inventories, net
24,815
35,664
Income tax receivable
2,048
2,976
Prepaid expenses and other current
assets
17,898
10,160
Total current assets
305,697
292,219
Property and equipment, net
28,230
19,438
Goodwill
33,165
32,954
Intangible assets, net
68,797
77,533
Operating lease right-of-use asset
8,827
5,855
Deferred tax asset - noncurrent
14,467
14,452
Other assets
2,669
4,888
Total assets
$
461,852
$
447,339
Liabilities and stockholders'
equity
Current liabilities
Accounts payable and accrued expenses
$
33,712
$
30,730
Accrued payroll
7,091
6,215
Warranty reserve - current
5,740
4,923
Operating lease liability - current
1,931
2,014
Deferred revenue - current
6,994
5,478
Income tax payable
1,242
821
Total current liabilities
56,710
50,181
Warranty reserve - noncurrent
8,654
7,648
Operating lease liability - noncurrent
8,078
4,702
Earnout liability - noncurrent
26,940
26,559
Deferred revenue - noncurrent
11,822
13,541
Deferred tax liability - noncurrent
25
87
Total liabilities
112,229
102,718
Stockholders' equity
Common stock
22
22
Additional paid-in capital
273,521
263,252
Retained earnings
75,605
81,434
Accumulated other comprehensive income
(loss)
475
(87
)
Total stockholders' equity
349,623
344,621
Total liabilities and stockholders'
equity
$
461,852
$
447,339
Consolidated Statements of
Comprehensive Income (Loss)
(unaudited)
(amounts in thousands, except
share and per share amounts)
Three months ended
Twelve months ended
December 31,
December 31,
2020
2019
2020
2019
Revenue
Sales revenue
$
64,628
$
73,473
$
280,189
$
340,546
Rental revenue
9,350
5,444
28,298
21,397
Total revenue
73,978
78,917
308,487
361,943
Cost of revenue
Cost of sales revenue
35,850
41,908
156,764
175,974
Cost of rental revenue, including
depreciation of $1,700 and $1,472 for the three months ended and
$5,695 and $6,253 for the twelve months ended, respectively
4,069
3,087
13,543
14,108
Total cost of revenue
39,919
44,995
170,307
190,082
Gross profit
34,059
33,922
138,180
171,861
Operating expense
Research and development
3,674
3,628
14,080
9,401
Sales and marketing
25,389
25,544
97,520
105,550
General and administrative
10,518
10,071
38,605
37,121
Total operating expense
39,581
39,243
150,205
152,072
Income (loss) from operations
(5,522
)
(5,321
)
(12,025
)
19,789
Other income (expense)
Interest income
67
835
909
4,712
Other income (expense)
250
249
5,836
(229
)
Total other income, net
317
1,084
6,745
4,483
Income (loss) before provision
(benefit) for income taxes
(5,205
)
(4,237
)
(5,280
)
24,272
Provision (benefit) for income
taxes
(84
)
(2,862
)
549
3,322
Net income (loss)
$
(5,121
)
$
(1,375
)
$
(5,829
)
$
20,950
Other comprehensive income (loss), net
of tax
Change in foreign currency translation
adjustment
452
217
857
(123
)
Change in net unrealized gains (losses) on
foreign currency hedging
(244
)
(612
)
(82
)
(1,566
)
Less: reclassification adjustment for net
(gains) losses included in net income
(140
)
76
(207
)
872
Total net change in unrealized gains
(losses) on foreign currency hedging
(384
)
(536
)
(289
)
(694
)
Change in net unrealized gains (losses) on
marketable securities
—
(12
)
(6
)
6
Total other comprehensive income
(loss), net of tax
68
(331
)
562
(811
)
Comprehensive income (loss)
$
(5,053
)
$
(1,706
)
$
(5,267
)
$
20,139
Basic net income (loss) per share
attributable to common stockholders (1)
$
(0.23
)
$
(0.06
)
$
(0.27
)
$
0.96
Diluted net income (loss) per share
attributable to common stockholders (1)(2)
$
(0.23
)
$
(0.06
)
$
(0.27
)
$
0.94
Weighted-average number of shares used
in calculating net income (loss) per share attributable to common
stockholders:
Basic common shares
22,042,288
21,878,004
21,980,326
21,821,104
Diluted common shares
22,042,288
21,878,004
21,980,326
22,241,064
(1)
Reconciliations of net income attributable
to common stockholders basic and diluted can be found in Inogen’s
Annual Report on Form 10-K to be filed with the Securities and
Exchange Commission.
(2)
Due to a net loss for the three and twelve
months ended December 31, 2020, and for the three months ended
December 31, 2019, diluted loss per share is the same as basic.
Supplemental Financial
Information
(unaudited)
(in thousands, except units
and patients)
Three months ended
Twelve months ended
December 31,
December 31,
2020
2019
2020
2019
Revenue by region and category
Business-to-business domestic sales
$
24,249
$
20,571
$
96,423
$
106,428
Business-to-business international
sales
13,609
17,101
62,147
77,960
Direct-to-consumer domestic sales
26,770
35,801
121,619
156,158
Direct-to-consumer domestic rentals
9,350
5,444
28,298
21,397
Total revenue
$
73,978
$
78,917
$
308,487
$
361,943
Additional financial measures
Units sold
40,800
42,600
178,900
201,100
Net rental patients as of period-end
32,200
25,300
32,200
25,300
Reconciliation of U.S. GAAP to
Other Non-GAAP Financial Measures
(unaudited)
(in thousands)
Three months ended
Twelve months ended
December 31,
December 31,
Non-GAAP EBITDA and Adjusted
EBITDA
2020
2019
2020
2019
Net income (loss)
$
(5,121
)
$
(1,375
)
$
(5,829
)
$
20,950
Non-GAAP adjustments:
Interest income
(67
)
(835
)
(909
)
(4,712
)
Provision (benefit) for income taxes
(84
)
(2,862
)
549
3,322
Depreciation and amortization
4,927
4,618
18,581
13,834
EBITDA (non-GAAP)
(345
)
(454
)
12,392
33,394
Stock-based compensation
2,092
2,199
8,203
9,129
Change in fair value of earnout
liability
1,219
810
1,053
810
Adjusted EBITDA (non-GAAP)
$
2,966
$
2,555
$
21,648
$
43,333
Three months ended
Twelve months ended
December 31,
2020
December 31,
2019
December 31,
2020
December 31,
2019
Non-GAAP international constant
currency revenue
(using 2019
FX rates)
(using 2018
FX rates)
(using 2019
FX rates)
(using 2018
FX rates)
International revenues (GAAP)
$
13,609
$
17,101
$
62,147
$
77,960
Foreign exchange impact
(586
)
475
(228
)
3,142
International constant currency revenues
(non-GAAP)
$
13,023
$
17,576
$
61,919
$
81,102
International revenue growth (GAAP)
-20.4
%
-7.7
%
-20.3
%
0.8
%
International constant currency revenue
growth (non-GAAP)
-23.8
%
-5.1
%
-20.6
%
4.9
%
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005911/en/
Investor Relations Contact: Matthew Pigeon
mpigeon@inogen.net
Media Contact: Byron Myers 805-562-0503
Inogen (NASDAQ:INGN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024